Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.38 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.38 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.38 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 12/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399563 | 1.00 | CDK1 (0.44) | CDK1CCNB1CCNE1CDK2KDM4E | |
| SCHEMBL24500614 | 0.84 | KDM4E (0.42) | KDM4EKMT2APDE9APDE1CPI4KA | |
| SCHEMBL31403622 | 0.83 | ADORA2A (0.46) | KDM4EKMT2APDE9APDE1C | |
| SCHEMBL24500179 | 0.83 | KDM4E (0.41) | CDK1KDM4EKMT2APDE9APDE1C | |
| SCHEMBL31403538 | 0.83 | KDM4E (0.41) | CDK1CCNB1CCNE1CDK2KDM4E | |
| SCHEMBL30096023 | 0.82 | MTOR (0.41) | CDK1CCNB1CCNE1CDK2KDM4E | |
| SCHEMBL30382424 | 0.80 | KDM4E (0.40) | CDK1KDM4EKMT2APDE9APDE1C | |
| Hydrochloric Acid SCHEMBL29389071 | 0.79 | KDM4E (0.39) | KDM4EKMT2APDE9APDE1C | |
| SCHEMBL130702 | 0.76 | PI4KA (0.56) | CDK1CCNB1CCNE1CDK2KDM4E | |
| SCHEMBL12206789 | 0.75 | PI4KB (0.61) | KDM4EKMT2APIK3CAMTORPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2023-08-22 | — | — | US | disclosed |
| US-11512087-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20200317679-A1 | NOVEL MTOR INHIBITOR COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-10-08 | — | — | US | disclosed |
| US-20190315756-A1 | BRK INHIBITORY COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315756-A1 | BRK INHIBITORY COMPOUND | BRI3BP, BLK, BRSK2 | CDK1 639/4885CCNB1 1367/4885CCNE1 1615/4885 |
| US-20200317679-A1 | NOVEL MTOR INHIBITOR COMPOUNDS | MTOR, RICTOR, RPTOR | CDK1 148/4885CCNB1 1505/4885CCNE1 1377/4885 |
| US-11512087-B2 | BRK inhibitory compound | BRI3BP, BLK, BRSK2 | CDK1 639/4885CCNB1 1367/4885CCNE1 1615/4885 |
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | MTOR, RICTOR, RPTOR | CDK1 187/4885CCNB1 1770/4885CCNE1 1499/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CDK1 1126/4885CCNB1 3082/4885CCNE1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.